New stem cell transplant trial aims to control tough lymphoma
NCT ID NCT03922724
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 8 times
Summary
This study tests a stem cell transplant to control peripheral T-cell lymphoma in people whose cancer has not responded to standard treatments. Participants receive a donor's stem cells after chemotherapy or antibody therapy to prepare their body. The goal is to see if this approach can improve survival and reduce side effects like graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
National Marrow Donor Program
Minneapolis, Minnesota, 55401, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Strumming for the brain: could ukulele lessons sharpen minds in MS?
- Can a targeted antibody boost chemotherapy against a rare leukemia?
- Could a metabolic modulator help people with type 1 diabetes use insulin better?
- Supercharged immune cells aim to stop lymphoma comeback
- New drug shows promise for kidney disease patients
- CRISPR's diabetes cell therapy trial ends early